ACTA1 and Hepatic fibrosis: In comparison to CCL4 control: hAEC-ECV:- Lowered TGF-β in liver lysatesAll treatments:- Decreased liver fibrosis and α-SMA+ cells.- Decreased liver infiltrating macrophages (F4/80+)- Increased in M2 marker (CD206)